AstraZeneca buys ZS Pharma for $2.7 billion, pips Actelion

AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform

Leerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings report. Results came in relatively in line with consensus on both the top and bottom lines, with total revenue of $5.95B vs. $5.97B consensus. EPS was reported at $1.03 vs. $1.02.

Analyst Seamus Fernandez commented, "We are updating our AZN model post 3Q results, which came in... More

JPMorgan Downgrades ZS Pharma (ZSPH) to Neutral

JPMorgan downgraded ZS Pharma (NASDAQ: ZSPH) from Overweight to Neutral with a price target of $90.00 (from $75.00).

For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.

Shares of ZS Pharma closed at $89.04 yesterday.

Credit Suisse Downgrades ZS Pharma (ZSPH) to Neutral on Takeover

Credit Suisse downgraded ZS Pharma (NASDAQ: ZSPH) from Outperform to Neutral with a price target of $90.00 (from $67.00) after the company agreed to be acquired by AZN

For an analyst ratings summary and ratings history on ZS Pharma... More

William Blair Downgrades ZS Pharma (ZSPH) to Market Perform

William Blair downgraded ZS Pharma (NASDAQ: ZSPH) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.

Shares of ZS Pharma closed at $63.31 yesterday.

Relypsa (RLYP) Poised to Open Higher Following AstraZeneca (AZN)/ZS Pharma (ZSPH) Deal

Relypsa (NASDAQ: RLYP) shares are poised higher after AstraZeneca (NYSE: AZN) agreed to acquire ZS Pharma (NASDAQ: ZSPH) for $2.7 billion. Shares of Relypsa are set to open higher by 20%.

AstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal

AstraZeneca (NYSE: AZN) announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).

The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition... More